<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03786198</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 95/17</org_study_id>
    <nct_id>NCT03786198</nct_id>
  </id_info>
  <brief_title>Activity Program During Aromatase Inhibitor Therapy</brief_title>
  <official_title>A 24 Weeks Activity Program in Patients With Early Breast Cancer Receiving Aromatase Inhibitor Therapy. A Multicenter Randomized Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the trial is to investigate if a simple outdoor walking intervention,
      which is practicable under real-life conditions, beginning at the start of adjuvant aromatase
      inhibitor (AI) therapy, can prevent the occurrence of muscle or joint pain/stiffness in
      breast cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After tumor removal, patients with hormone receptor positive breast cancer tumors often
      receive adjuvant endocrine treatment, with the use of an aromatase inhibitor (AI) being
      standard of care in the population of postmenopausal women. Common side effects of AI therapy
      are joint pain, muscle pain, stiffness, fatigue, hot flashes, and weight gain. Arthralgia
      and/or myalgia can result in lower physical activity and can negatively influence quality of
      life (QoL). In addition, muscle or joint pain/stiffness are among the main reasons for
      non-compliance and discontinuation of AI therapy. Because AI therapy is usually administered
      for 5 and sometimes even 10 years, this is a major clinical challenge.

      For breast cancer patients undergoing AI therapy, physical activity can provide potential
      benefit by reducing muscle/joint pain and fatigue and can thus improve QoL. The preventive
      effect of physical activity on AI side effects, however, remains elusive. In addition,
      activity programs to reduce AI side effects have so far mostly been rather complex. The
      primary aim of the trial is to investigate if a simple outdoor walking intervention, which is
      practicable under real-life conditions, beginning at the start of adjuvant AI therapy, can
      prevent the occurrence of muscle or joint pain/stiffness in breast cancer patients.

      Furthermore, this trial will assess the effect of physical activity on symptom burden in
      general and quality of life in patients receiving adjuvant AI therapy. During the follow-up
      phase, the trial will assess whether this intervention leads to a sustained change in
      lifestyle regarding activity, less pain, and better treatment adherence in the intervention
      group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2019</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Home-based walking intervention for 24 weeks + standard adjuvant AI therapy
Physical activity according to standard recommendations for 24 weeks + standard adjuvant AI therapy</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of muscle or joint pain/stiffness as measured by BPI-SF single-item worst pain score</measure>
    <time_frame>Up to 24 weeks after randomization</time_frame>
    <description>Muscle or joint pain/stiffness will be assessed at baseline, 3, 9, 12, 15, 18, 21, 24 weeks after randomization by the BPI-SF questionnaire.
The BPI-SF is a 14-item self-administered questionnaire which is routinely used in clinical trials to assess pain severity and pain interference with daily activities in patients with cancer. Pain severity is assessed by four items including pain at its &quot;worst&quot;, &quot;least&quot;, &quot;average&quot; in the last 24 hours and &quot;now&quot; (current pain), each item being rated on a 0-10 scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>Baseline, 12 and 24 weeks and 1 and 2 years after randomization</time_frame>
    <description>Fatigue will be assessed at baseline, during intervention phase and during follow-up phase using the corresponding symptom scale of the EORTC QLQ-C30 version 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL: Physical scale (EORTC QLQ-C30)</measure>
    <time_frame>Baseline, 12 and 24 weeks and 1 and 2 years after randomization</time_frame>
    <description>Physical scale will be assessed at baseline, during intervention phase and during follow-up phase using the corresponding symptom scale of the EORTC QLQ-C30 version 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL: Rose scale (EORTC QLQ-C30)</measure>
    <time_frame>Baseline, 12 and 24 weeks and 1 and 2 years after randomization</time_frame>
    <description>Role scale will be assessed at baseline, during intervention phase and during follow-up phase using the corresponding symptom scale of the EORTC QLQ-C30 version 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL: Emotional scale (EORTC QLQ-C30)</measure>
    <time_frame>Baseline, 12 and 24 weeks and 1 and 2 years after randomization</time_frame>
    <description>Emotional scale will be assessed at baseline, during intervention phase and during follow-up phase using the corresponding symptom scale of the EORTC QLQ-C30 version 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL: Cognitive scale (EORTC QLQ-C30)</measure>
    <time_frame>Baseline, 12 and 24 weeks and 1 and 2 years after randomization</time_frame>
    <description>Cognitive scale will be assessed at baseline, during intervention phase and during follow-up phase using the corresponding symptom scale of the EORTC QLQ-C30 version 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL: Social functioning scale (EORTC QLQ-C30)</measure>
    <time_frame>Baseline, 12 and 24 weeks and 1 and 2 years after randomization</time_frame>
    <description>Cognitive scale will be assessed at baseline, during intervention phase and during follow-up phase using the corresponding symptom scale of the EORTC QLQ-C30 version 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nausea/Vomiting</measure>
    <time_frame>Baseline, 12 and 24 weeks and 1 and 2 years after randomization</time_frame>
    <description>Nausea/vomiting will be assessed at baseline, during intervention phase and during follow-up phase using the corresponding symptom scale of the EORTC QLQ-C30 version 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain (EORTC QLQ-C30)</measure>
    <time_frame>Baseline, 12 and 24 weeks and 1 and 2 years after randomization</time_frame>
    <description>Pain will be assessed at baseline, during intervention phase and during follow-up phase using the corresponding symptom scale of the EORTC QLQ-C30 version 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global health status</measure>
    <time_frame>Baseline, 12 and 24 weeks and 1 and 2 years after randomization</time_frame>
    <description>Global health status will be assessed at baseline, during intervention phase and during follow-up phase using the corresponding symptom scale of the EORTC QLQ-C30 version 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnoea</measure>
    <time_frame>Baseline, 12 and 24 weeks and 1 and 2 years after randomization</time_frame>
    <description>Dyspnoea will be assessed at baseline, during intervention phase and during follow-up phase using the corresponding symptom scale of the EORTC QLQ-C30 version 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insomnia</measure>
    <time_frame>Baseline, 12 and 24 weeks and 1 and 2 years after randomization</time_frame>
    <description>Insomnia will be assessed at baseline, during intervention phase and during follow-up phase using the corresponding symptom scale of the EORTC QLQ-C30 version 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite loss</measure>
    <time_frame>Baseline, 12 and 24 weeks and 1 and 2 years after randomization</time_frame>
    <description>Appetite loss will be assessed at baseline, during intervention phase and during follow-up phase using the corresponding symptom scale of the EORTC QLQ-C30 version 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Constipation</measure>
    <time_frame>Baseline, 12 and 24 weeks and 1 and 2 years after randomization</time_frame>
    <description>Constipation will be assessed at baseline, during intervention phase and during follow-up phase using the corresponding symptom scale of the EORTC QLQ-C30 version 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diarrhoea</measure>
    <time_frame>Baseline, 12 and 24 weeks and 1 and 2 years after randomization</time_frame>
    <description>Diarrhoea will be assessed at baseline, during intervention phase and during follow-up phase using the corresponding symptom scale of the EORTC QLQ-C30 version 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Financial difficulties</measure>
    <time_frame>Baseline, 12 and 24 weeks and 1 and 2 years after randomization</time_frame>
    <description>Financial difficulties will be assessed at baseline, during intervention phase and during follow-up phase using the corresponding symptom scale of the EORTC QLQ-C30 version 3.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hot flashes</measure>
    <time_frame>Baseline, 12 and 24 weeks and 1 and 2 years after randomization</time_frame>
    <description>Hot flashes will be assessed at baseline, during intervention phase and during follow-up phase via the item 37 of the EORTC QLQ BR-23.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensity of muscle or joint pain/stiffness and its impact on everyday functioning</measure>
    <time_frame>Baseline, 3, 9, 12, 15, 18, 21, 24 weeks and 1, 2 years after randomization</time_frame>
    <description>Severity of muscle or joint pain/stiffness will be measured by the four BPI pain severity items. Pain interference will be calculated as the mean of the seven interference items.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking activity</measure>
    <time_frame>Baseline, 3, 9, 12, 15, 18, 21, 24 weeks after randomization</time_frame>
    <description>During trial intervention phase, daily steps will be measured by a wrist worn activity tracker.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AI treatment adherence (diary)</measure>
    <time_frame>Baseline, 3, 9, 12, 15, 18, 21, 24 weeks.</time_frame>
    <description>Adherence will be assessed by patient self-report (diary).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AI treatment adherence (questionnaire)</measure>
    <time_frame>Baseline, 12, 24 weeks and 1, 2 years after randomization</time_frame>
    <description>Adherence will be assessed by patient self-report (questionnaire completed at visits).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Early Breast Cancer</condition>
  <arm_group>
    <arm_group_label>a) Home-based walking intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Home-based walking intervention, wearing a wrist worn activity tracker, for 24 weeks + standard adjuvant AI therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>b) Physical activity according to standard recommendations</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Physical activity according to standard recommendations, wearing a wrist worn activity tracker (with no feedback about performed activity), for 24 weeks + standard adjuvant AI therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Activity program</intervention_name>
    <description>Home-based walking intervention, wearing a wrist worn activity tracker, for 24 weeks</description>
    <arm_group_label>a) Home-based walking intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Physical activity according to standard recommendations, wearing a wrist worn activity tracker (with no feedback about performed activity), for 24 weeks + standard adjuvant AI therapy</description>
    <arm_group_label>b) Physical activity according to standard recommendations</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent according to Swiss law and ICH/GCP regulations before
             registration and prior to any trial specific procedures.

          -  Histologically confirmed hormone-receptor-positive newly diagnosed breast cancer, AJCC
             (American Joint Committee on Cancer) stage I-III

          -  Patient had tumor removal by breast conserving surgery or mastectomy, followed by
             chemotherapy (if indicated) and/or radiotherapy (if indicated)

          -  Patient is starting adjuvant first-line endocrine treatment with an AI alone (in
             postmenopausal women) or combined endocrine treatment with an AI and ovarian
             suppression with an LHRH-agonist (in premenopausal women)

          -  Patient completed the PRO Form Eligibility before registration

          -  Patient is fluent in German, Italian, or French

          -  Patient is willing to wear a wrist worn activity tracker for 24 weeks

          -  Female patient, age ≥ 18 years

          -  WHO performance status 0-2

        Exclusion Criteria:

          -  Pre-existing severe medical conditions such as heart or lung problems or
             musculoskeletal conditions precluding participation in the physical activity program
             of moderate walking a total of 150 minutes per week as determined by the local
             investigator

          -  Mild, moderate, or severe pain (other than post-operative pain) in the last 24 hours
             due to muscle/joint pain on the BPI-SF single item &quot;worst pain&quot; (&quot;worst pain&quot; ≥3)
             within 7 days prior to registration

          -  Inoperable, locally advanced and/or metastatic breast cancer

          -  Active rheumatoid arthritis

          -  Neoadjuvant endocrine treatment with an AI

          -  NSAIDs, acetaminophen or opioids on a regular basis (&gt; 1 time per week)

          -  Concurrent participation in other clinical trials or observational studies

          -  Any other serious psychological, familial or geographical condition, which in the
             judgment of the investigator may interfere with the intervention and follow-up or
             affect patient compliance with trial procedures.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Friedemann Honecker, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Tumor und Brustzentrum ZeTuP, St. Gallen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicolette Hoefnagels, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Tumor und Brustzentrum ZeTuP, St. Gallen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniele Oberti, PhD</last_name>
    <phone>+41 31 389 91 91</phone>
    <email>trials@sakk.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dimitri Sarlos, MD</last_name>
      <phone>+41 62 838 50 65</phone>
      <email>Dimitri.Sarlos@ksa.ch</email>
    </contact>
    <investigator>
      <last_name>Dimitri Sarlos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cornelia Leo, MD</last_name>
      <phone>+41 56 486 21 11</phone>
      <email>cornelia.leo@ksb.ch</email>
    </contact>
    <investigator>
      <last_name>Cornelia Leo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CABA - Zentrum für Onkologie, Psychologie und Bewegung</name>
      <address>
        <city>Basel</city>
        <zip>4051</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathrine Balmelli, MD</last_name>
      <phone>+41 61 511 25 40</phone>
      <email>c.balmelli@caba-basel.ch</email>
    </contact>
    <investigator>
      <last_name>Cathrine Balmelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brustzentrum Basel - Praxis für ambulante Tumortherapie</name>
      <address>
        <city>Basel</city>
        <zip>4052</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Roger Thorn, MD</last_name>
      <phone>+41 61 279 98 22</phone>
      <email>dr.david.thorn@hin.ch</email>
    </contact>
    <investigator>
      <last_name>David Roger Thorn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcus Vetter, MD</last_name>
      <phone>+41 61 265 25 25</phone>
      <email>marcus.vetter@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Marcus Vetter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franziska Zenger, MD</last_name>
      <phone>+41 31 632 21 11</phone>
      <email>franziska.zenger@insel.ch</email>
    </contact>
    <investigator>
      <last_name>Franziska Zenger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hirslanden Brustzentrum Bern Biel</name>
      <address>
        <city>Bern</city>
        <zip>3013</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizia Sager, MD</last_name>
      <phone>+41 31 337 89 70</phone>
      <email>patrizia.sager@hirslanden.ch</email>
    </contact>
    <investigator>
      <last_name>Patrizia Sager, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Schwitter, MD</last_name>
      <phone>+41 81 256 75 68</phone>
      <email>michael.schwitter@ksgr.ch</email>
    </contact>
    <investigator>
      <last_name>Michael Schwitter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tumorzentrum ZeTuP Chur</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katja Zirlik, Prof</last_name>
      <phone>+41 81 257 01 30</phone>
      <email>katja.zirlik@zetup.ch</email>
    </contact>
    <investigator>
      <last_name>Katja Zirlik, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique des Grangettes, Centre du sein</name>
      <address>
        <city>Chêne-Bougeries</city>
        <zip>1224</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahbiz Nobahar Corke, MD</last_name>
      <phone>+41 22 545 80 06</phone>
      <email>mahbiz.nobahar@grangettes.ch</email>
    </contact>
    <investigator>
      <last_name>Mahbiz Nobahar Corke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brustzentrum Thurgau</name>
      <address>
        <city>Frauenfeld</city>
        <zip>8501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Fehr, Prof</last_name>
      <phone>+41 52 723 72 56</phone>
      <email>mathias.fehr@stgag.ch</email>
    </contact>
    <investigator>
      <last_name>Mathias Fehr, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre du sein Fribourg / Brustzentrum Freiburg</name>
      <address>
        <city>Fribourg</city>
        <zip>1700</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Rosset, MD</last_name>
      <phone>+41 26 347 43 07</phone>
      <email>rossetl@hin.ch</email>
    </contact>
    <investigator>
      <last_name>Laurent Rosset, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique De Genolier</name>
      <address>
        <city>Genolier</city>
        <zip>1272</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Kirchner, MD</last_name>
      <phone>+41 22 366 94 42</phone>
      <email>vkirchner@genolier.net</email>
    </contact>
    <investigator>
      <last_name>Volker Kirchner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>FOLM - Fondazione Oncologia Lago Maggiore</name>
      <address>
        <city>Locarno</city>
        <zip>6600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michail Kouros, MD</last_name>
      <phone>+41 91 751 82 30</phone>
      <email>mk@pedrazzini-kouros.ch</email>
    </contact>
    <investigator>
      <last_name>Michail Kouros, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia Varini&amp;Calderoni&amp;Christinat</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonello Calderoni, MD</last_name>
      <phone>+41 91 922 69 88</phone>
      <email>antonello.calderoni@swissoncology.com</email>
    </contact>
    <investigator>
      <last_name>Antonello Calderoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Luzerne</city>
        <zip>CH-6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Aebi, Prof</last_name>
      <phone>+41 41 205 58 60</phone>
      <email>stefan.aebi@onkologie.ch</email>
    </contact>
    <investigator>
      <last_name>Stefan Aebi, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hirslanden Klinik St. Anna</name>
      <address>
        <city>Luzern</city>
        <zip>6006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Dubsky, MD</last_name>
      <phone>+41 41 208 37 53</phone>
      <email>peter.dubsky@hirslanden.ch</email>
    </contact>
    <investigator>
      <last_name>Peter Dubsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkologie Zentrum Spital Männedorf</name>
      <address>
        <city>Manno</city>
        <zip>8708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Hochstrasser, MD</last_name>
      <phone>+41 44 922 30 00</phone>
      <email>a.hochstrasser@spital.maennedorf.ch</email>
    </contact>
    <investigator>
      <last_name>Andreas Hochstrasser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli</name>
      <address>
        <city>Mendrisio</city>
        <zip>6850</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Di Lascio, MD</last_name>
      <phone>+41 91 811 34 03</phone>
      <email>simona.dilascio@eoc.ch</email>
    </contact>
    <investigator>
      <last_name>Simona Di Lascio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Neuchâtelois</name>
      <address>
        <city>Neuenhof</city>
        <zip>2000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amina Chouiter-Djebaili, MD</last_name>
      <phone>+41 32 713 30 00</phone>
      <email>amina-faiza.chouiter-djebaili@h-ne.ch</email>
    </contact>
    <investigator>
      <last_name>Amina Chouiter-Djebaili, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Olten</name>
      <address>
        <city>Olten</city>
        <zip>4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catrina Uhlmann Nussbaum, MD</last_name>
      <phone>+41 62 311 42 41</phone>
      <email>cuhlmann_ol@spital.ktso.ch</email>
    </contact>
    <investigator>
      <last_name>Catrina Uhlmann Nussbaum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tumorzentrum ZeTuP Rapperswil-Jona</name>
      <address>
        <city>Rapperswil-Jona</city>
        <zip>8640</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Egger, MD</last_name>
      <phone>+41 55 536 13 00</phone>
      <email>matthias.egger@zetup.ch</email>
    </contact>
    <investigator>
      <last_name>Matthias Egger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brustzentrum Ostschweiz</name>
      <address>
        <city>Saint Gallen</city>
        <zip>9016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrik Weder, MD</last_name>
      <phone>+41 71 552 33 33</phone>
      <email>patrik.weder@bz-ost.ch</email>
    </contact>
    <investigator>
      <last_name>Patrik Weder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rundum Onkologie am Bahnhofpark</name>
      <address>
        <city>Sargans</city>
        <zip>7320</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Greuter, MD</last_name>
      <phone>+41 81 720 06 20</phone>
      <email>rundum@hin.ch</email>
    </contact>
    <investigator>
      <last_name>Stefan Greuter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de Sion</name>
      <address>
        <city>Sion</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronique Membrez, MD</last_name>
      <phone>+41 27 603 48 53</phone>
      <email>veronique.membrez@hopitalvs.ch</email>
    </contact>
    <investigator>
      <last_name>Véronique Membrez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tumorzentrum ZeTUP</name>
      <address>
        <city>St. Gallen</city>
        <zip>9006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friedemann Honecker, MD</last_name>
      <phone>+41 71 243 00 43</phone>
      <email>friedemann.honecker@zetup.ch</email>
    </contact>
    <investigator>
      <last_name>Friedemann Honecker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salome Riniker, MD</last_name>
      <phone>+41 71 494 19 77</phone>
      <email>salome.riniker@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Salome Riniker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regionalspital Thun</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Marc Lüthi, MD</last_name>
      <phone>+41 58 636 26 45</phone>
      <email>jean-marc.luethi@spitalstsag.ch</email>
    </contact>
    <investigator>
      <last_name>Jean-Marc Lüthi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur, Brustzentrum</name>
      <address>
        <city>Winterthur</city>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Müller, MD</last_name>
      <phone>+41 52 266 25 52</phone>
      <email>andreas.mueller@ksw.ch</email>
    </contact>
    <investigator>
      <last_name>Andreas Müller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkologie Bellevue</name>
      <address>
        <city>Zurich</city>
        <zip>8001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Basil A. Bättig, MD</last_name>
      <phone>+41 44 261 61 11</phone>
      <email>bbaettig@hin.ch</email>
    </contact>
    <investigator>
      <last_name>Basil A. Bättig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brustzentrum Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Güth, Prof</last_name>
      <phone>+41 44 380 76 60</phone>
      <email>u.gueth@brust-zentrum.ch</email>
    </contact>
    <investigator>
      <last_name>Uwe Güth, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts Spital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantin Dedes, MD</last_name>
      <phone>+41 44 255 11 11</phone>
      <email>konstantin.dedes@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Konstantin Dedes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 14, 2018</study_first_submitted>
  <study_first_submitted_qc>December 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2018</study_first_posted>
  <last_update_submitted>May 11, 2020</last_update_submitted>
  <last_update_submitted_qc>May 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>early breast cancer</keyword>
  <keyword>aromatase inhibitor therapy</keyword>
  <keyword>activity program</keyword>
  <keyword>physical activity</keyword>
  <keyword>activity tracker</keyword>
  <keyword>pedometer</keyword>
  <keyword>stepcounter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

